Clinical trials: sponsored by Amgen
Pre-Dialysis
Phase 2 Study of Darbepoetin Alfa Extended Dosing
Multicenter, open label single arm study in which 140 subjects with CRI who are currently receiving SC darbepoetin alfa once every other week will receive darbepoetin alfa once every 4 weeks for 24 weeks.
- Trial name
- NCT00527215
- Testing
- darbepoetin alfa
- Volunteers
- 98 people
- Sponsor
- Amgen
Anemia, Cancer
A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AMG 114 administered subcutaneously for the treatment of chemotherapy induced anemia in subjects receiving multicycle chemotherapy.
- Trial name
- NCT00119600
- Testing
- AMG 114
- Sponsor
- Amgen
Lymphoma, Breast Neoplasms
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. The symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath.
- Conditions
- Lymphoma, Breast Neoplasms, Lung Neoplasms, Multiple Myeloma
- Trial name
- NCT00036023
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Anemia, Cancer
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
The purpose of this study is to determine the safety of darbepoetin alfa beyond 16 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy.
- Trial name
- NCT00115167
- Testing
- Darbepoetin alfa
- Volunteers
- 371 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy
The purpose of this study is to estimate the relationship between patient reported outcomes (PROs) and neutropenia (or its complications) in NSCLC subjects receiving chemotherapy with or without Neulasta® (pegfilgrastim).
- Trial name
- NCT00115206
- Testing
- Neulasta® (pegfilgrastim)
- Sponsor
- Amgen
Neoplasms, Anemia
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
The purpose of this study is to assess the ability of darbepoetin alfa to maintain hemoglobin concentrations greater than or equal to 10 g/dL when administered every 3 weeks (Q3W).
- Trial name
- NCT00120705
- Testing
- darbepoetin alfa
- Volunteers
- 204 people
- Sponsor
- Amgen
Anemia
A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with Aranesp®.
- Trial name
- NCT00117117
- Testing
- Aranesp
- Volunteers
- 2,423 people
- Sponsor
- Amgen
Anemia
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
The purpose of this trial is to demonstrate benefit with respect to hematopoietic response in subjects with anemia of cancer randomized to Darbepoetin Alfa once every 4 weeks.
- Trial name
- NCT00095277
- Testing
- Darbepoetin Alfa
- Volunteers
- 220 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to evaluate the safety of an additional 28 weeks of treatment with pegsunercept for subjects who have completed treatment in a previous double-blind study (20000201 or 20000198).
- Trial name
- NCT00111423
- Testing
- Pegsunercept (PEG sTNF-RI)
- Volunteers
- 216 people
- Sponsor
- Amgen
Inflammation, Psoriasis
Study of Etanercept in the Treatment of Psoriasis in Adult Subjects
The objective of the study is to describe the safety, tolerability, and efficacy of the long-term administration of etanercept in adults with psoriasis who have completed etanercept psoriasis study 20030115 or 20030117, in…
- Trial name
- NCT00121615
- Testing
- etanercept
- Volunteers
- 391 people
- Sponsor
- Amgen
Kidney Disease, Secondary Hyperparathyroidism
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary…
- Conditions
- Kidney Disease, Secondary Hyperparathyroidism, Chronic Kidney Disease
- Trial name
- NCT00132431
- Testing
- Sensipar
- Volunteers
- 300 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Etanercept SFP in RA Patients
Purpose of this study is to evaluate the immunogenicity and overall safety of etanercept SFP therapy administered once weekly for 24 weeks to subjects with rheumatoid arthritis.
- Trial name
- NCT00413452
- Testing
- Etanercept
- Volunteers
- 224 people
- Sponsor
- Amgen
Lung Cancer, Non-Small Cell Lung Cancer
Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this research study is to evaluate the safety and effectiveness of Neulasta® (pegfilgrastim) in reducing infection when given on the same day versus one day after the completion of chemotherapy (docetaxel and…
- Trial name
- NCT00094822
- Testing
- PI Discretion
- Volunteers
- 90 people
- Sponsor
- Amgen
Ovarian Cancer
Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer
This trial will provide data on the safety and efficacy of pegfilgrastim, in terms of duration of grade 4 neutropenia, when administered on the last day or the day after a multi-day, myelosuppressive chemotherapy regimen for…
- Trial name
- NCT00113789
- Testing
- PI Discretion
- Volunteers
- 21 people
- Sponsor
- Amgen
Hyperparathyroidism
Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects
Subjects on Hemodialysis will be randomized to AMG 073 or placebo. The screening period is a maximum of 30 days followed by a 26-week treatment period.
- Trial name
- NCT00527267
- Testing
- AMG 073
- Volunteers
- 320 people
- Sponsor
- Amgen
Rheumatoid Arthritis
REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations
The purpose of this study is to determine if Enbrel® or Kineret® will have a positive effect on subject functionality as measured by the Health Assessment Questionnaire Disability Index (HAQDI).
- Trial name
- NCT00121056
- Testing
- Enbrel®, Kineret®
- Sponsor
- Amgen
Rheumatoid Arthritis
Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes
The purpose of this study is to determine the preference of RA patients for the new Enbrel® (etanercept) pre-filled syringe in patients who are already taking Enbrel®.
- Trial name
- NCT00094341
- Testing
- Etanercept
- Volunteers
- 215 people
- Sponsor
- Amgen
Myeloid Leukemia
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
The purpose of this study is to determine if a single dose of pegfilgrastim is able to reduce the time of severe neutropenia in patients receiving induction and consolidation myelosuppressive chemotherapy for de novo acute…
- Trial name
- NCT00114764
- Testing
- filgrastim, pegfilgrastim
- Volunteers
- 84 people
- Sponsor
- Amgen
Anemia, Neoplasms
A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia
The purpose of this trial is to assess the effectiveness of Aranesp® administered at 300 mcg every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and maintaining hemoglobin levels consistent with…
- Trial name
- NCT00117039
- Testing
- Aranesp®
- Volunteers
- 1,500 people
- Sponsor
- Amgen
Kidney Disease
Aranesp® Monthly Preference Study - 2
The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
- Trial name
- NCT00117078
- Testing
- Aranesp®
- Sponsor
- Amgen